Hiv integrase - Open Access .click

Results 21 to 30 of about 18,464 (76)

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

MedComm, Volume 6, Issue 4, April 2025.
Peptide PROTAC is a bifunctional molecule generally composed of a target protein binding peptide (TBP), a linker peptide (LP), an E3 ligase binding peptide (EBP), and a delivery‐enhancing peptide (DEP), which can bind to the target protein (P) and E3 ligase (E3), inducing P to be labeled with ubiquitin (Ub) and subsequently recognized and degraded by ...
Youmin Zhu, Yu Dai, Yuncai Tian
wiley +1 more source

Inhibition of lipid synthesis by the HIV integrase strand transfer inhibitor elvitegravir in primary rat oligodendrocyte cultures. [PDF]

Front Mol Neurosci, 2023
Monnerie H +6 more
europepmc +1 more source

Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders

Cell Proliferation, Volume 58, Issue 4, April 2025.
This review outlines the latest research advancements in prime editing technology, delivery strategies, and the challenges that must be addressed to fully realize its therapeutic potential, emphasizing the high potential of prime editing in the remission or cure of genetic diseases. ABSTRACT Genetic diseases have long posed significant challenges, with
Mengyao Li, Yi Lin, Qiang Cheng, Tuo Wei
wiley +1 more source

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. [PDF]

Retrovirology, 2022
Zhao AV +5 more
europepmc +1 more source

Point‐of‐care nucleic acid testing – a step forward in controlling the HIV epidemic: A review

HIV Medicine, Volume 26, Issue 4, Page 536-545, April 2025.
Abstract Introduction The HIV/AIDS epidemic, with 85.6 million infections and 40.4 million AIDS‐related deaths globally, remains a critical public health challenge. Current diagnostic methods, primarily fourth‐generation immunoassays, have limitations due to their long window periods, and most viral load assays require centralized testing protocols ...
Suleyman Sarp Pinar +4 more
wiley +1 more source

First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. [PDF]

Biochem Biophys Rep, 2022
Ghasabi F +6 more
europepmc +1 more source

A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda

HIV Medicine, Volume 26, Issue 4, Page 592-605, April 2025.
Abstract Introduction Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir‐based regimens to inform HIV programmes.
Eva Agnes Laker Odongpiny +12 more
wiley +1 more source

HIV Medicine, Volume 26, Issue 4, Page 606-620, April 2025.
Abstract Objectives We aimed to describe health‐related quality of life (HRQoL), overall and across its dimensions, identify associated factors, and assess changes over time among people with HIV (PWH) from the Spanish multicentre CoRIS cohort.
Rebeca Izquierdo +429 more
wiley +1 more source

Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir

HIV Medicine, Volume 26, Issue 4, Page 650-653, April 2025.
Abstract Objectives This study aimed to evaluate the HIV virological efficacy of two‐drug regimens (2DR) with lamivudine (3TC) and dolutegravir (DTG) in people with HIV (PWH), classified by their hepatitis B virus (HBV) serological status. Specifically, it explored whether isolated anti‐hepatitis B core (anti‐HBc) positivity impacts virological ...
Pierluigi Francesco Salvo +6 more
wiley +1 more source

Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes. [PDF]

Cells, 2022
Ngono Ayissi K +16 more
europepmc +1 more source